NCT00004941 2015-03-25
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
FDA Office of Orphan Products Development
Phase 3 Completed